- Report
- January 2026
- 371 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 178 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 279 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 181 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 381 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 174 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 260 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 279 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 173 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 196 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 194 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 194 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 179 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 179 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 193 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 196 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 197 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 196 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 657 Pages
Global
From €5191EUR$5,850USD£4,494GBP
- Report
- January 2026
- 427 Pages
Global
From €5191EUR$5,850USD£4,494GBP

The Targeted Therapies market within the context of Genomics is focused on the development of treatments that target specific genetic mutations or pathways. These therapies are designed to be more effective and have fewer side effects than traditional treatments. Genomics has enabled the development of personalized treatments that are tailored to the individual patient's genetic makeup. This has allowed for the development of drugs that target specific mutations or pathways, leading to more effective treatments.
The Targeted Therapies market is a rapidly growing field, with many companies investing in research and development. Companies such as Gilead Sciences, Novartis, and AstraZeneca are leading the way in the development of targeted therapies. Other companies such as Merck, Pfizer, and Roche are also investing in the development of targeted therapies. Show Less Read more